Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZLAB Zai Lab Ltd

Trading 01-02 15:52:00 EST

17.28

-0.36

-2.04%

High17.58	Low17.24	Vol616.31K
Open17.43	D1 Closing17.64	Amplitude1.93%
Mkt Cap1.92B	Tradable Cap1.89B	Total Shares111.27M
T/O10.72M	T/O Rate0.56%	Tradable Shares109.37M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"Zai Lab Ltd","latestPrice":17.28,"timestamp":1767387119583,"preClose":17.64,"halted":0,"volume":616305,"delay":0,"floatShares":109371942,"shares":111270801,"eps":-1.922867,"marketStatus":"Trading","change":-0.36,"latestTime":"01-02 15:52:00 EST","open":17.43,"high":17.5809,"low":17.24,"amount":10717403.43246,"amplitude":0.019325,"askPrice":17.32,"askSize":178,"bidPrice":17.24,"bidSize":1912,"shortable":3,"etf":0,"ttmEps":-1.922867,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1767387600000},"marketStatusCode":2,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":17.64,"preHourTrading":{"tag":"盘前","latestPrice":17.5,"preClose":17.64,"latestTime":"09:28 EST","volume":1236,"amount":21832.792992000002,"timestamp":1767364099048},"postHourTrading":{"tag":"盘后","latestPrice":17.4,"preClose":17.64,"latestTime":"18:03 EST","volume":5546,"amount":97795.48,"timestamp":1767222216520},"volumeRatio":1.226586,"impliedVol":0.3066,"impliedVolPercentile":0.036},"requestUrl":"/m/hq/s/ZLAB/wiki","defaultTab":"wiki","newsList":[{"id":"2600613810","title":"Asian Equities Traded in the US as American Depositary Receipts Climb in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2600613810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600613810?lang=en_us&edition=fundamental","pubTime":"2026-01-02 23:47","pubTimestamp":1767368846,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were higher on Friday morning, up 2.4% to 2,762.97 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by finance and technology company Eason Technology  and tech giant Baidu , which climbed 34% and 12% respectively.They were followed by travel agency Tuniu  and data center operator GDS , which advanced 11% and nearly 8% respectively.The decliners from North Asia were led by electric vehicle maker Xpeng  and commercial-stage biopharmaceutical company Zai Lab , which fell 1.7% and 1.1% respectively.They were followed by utility Korea Electric Power , which declined 1%.From South Asia, the gainers were led by tech companies Infosys  and Wipro , which rose 1.7% and 1.4% respectively.The decliners from South Asia were led by pharmaceutical company Dr Reddy's Laboratories , which fell 2.5%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2087589342.USD","LU0359202008.SGD","LU0287143357.SGD","TOUR","LU0359201612.USD","LU0862451753.SGD","LU0531971678.HKD","LU1023057109.AUD","BK4574","LU1323998911.USD","LU0640798160.USD","LU1115378108.SGD","BK4535","BK4551","LU0173614495.USD","BK4587","DXF","BK4081","BK4533","RDY","09698","LU0287142896.SGD","LU1805238398.USD","BK4588","BK4543","WIT","IE00B0JY6M65.USD","09888","GDS","BK4585","LU1267930656.SGD","BK4107","BK4514","BK4523","LU0164881194.USD","BK4007","LU0348744763.USD","IE00BYTNYM70.SGD","09688","LU0708995666.HKD","BK4579","BK4134","BK4504","BK4526","LU1102505762.USD","LU2663582299.SGD","LU1508157978.USD","LU0898667661.SGD","BK4552","LU0831103253.SGD","BK4607","KEP","LU2488822045.USD","BK4548","LU2265009873.SGD","BIDU","BK7016","BK4142","EVS.SI","BK4099","ADRA","LU0791590937.USD","BK4077","LU0536402901.SGD","BK4557","BK4529","BK4164","BK4602","IE00B7N09G41.SGD","LU1366334651.USD","BK4555","INFY","BK4596","BK4505","IE00B0JY6N72.USD","BK4139","LU0231203729.USD","BK4563","LU0791591158.USD","LU0197229882.USD","LU0868486357.SGD","LU0066902890.USD","ZLAB","LU0890818403.SGD","LU1804176565.USD","BK4117","IE00B3M56506.USD","LU1366334578.USD","BK4116","BK4614","BK4612","LU0431992006.USD","BK4532","LU0333810181.USD","BK4531"],"gpt_icon":1},{"id":"1189613078","title":"HK Stock Movement | Zai Lab (09688) Rises Over 4% in Early Trading as Breakthrough Schizophrenia Drug KAI JIE LE Gains Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1189613078","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189613078?lang=en_us&edition=fundamental","pubTime":"2025-12-24 09:47","pubTimestamp":1766540845,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) surged more than 4% in early trading, reaching HK$14.1 with a turnover of HK$59.19 million by the time of reporting. The uptick follows the company's announcement on December 23 that...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK1588","BK1574","BK4548","LU2488822045.USD","BK4588","BK4526","BK1161","09688","BK4585","BK4139","ZLAB"],"gpt_icon":0},{"id":"2593775490","title":"Zai Lab Says New Drug Application for Schizophrenia Treatment Cobenfy Approved by China's National Medical Products Administration","url":"https://stock-news.laohu8.com/highlight/detail?id=2593775490","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593775490?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:09","pubTimestamp":1766495343,"startTime":"0","endTime":"0","summary":"Zai Lab  said Tuesday that China's National Medical Products Administration has approved its new drug application for Cobenfy for the treatment of schizophrenia in adults.The approval is supported by the results of a phase 1 and a phase 3 clinical trials in China, as well as three global Emergent clinical trials, the company said.China Schizophrenia Prevention and Treatment Guidelines already include Cobenfy as a novel treatment for schizophrenia, Zai Lab added.Shares of the company rose more than 1% in recent pre-bell activity Tuesday.Price: 17.95, Change: +0.24, Percent Change: +1.36","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU2488822045.USD","NHLD","BK4585","BK4531","ZLAB","BK4526","BK4548","BK4588"],"gpt_icon":0},{"id":"2592163037","title":"How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163037","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592163037?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:21","pubTimestamp":1766136083,"startTime":"0","endTime":"0","summary":"Zai Lab Limited recently dosed the first participant in a global randomized, double-blind, placebo-controlled Phase 1/1b trial of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for moderate-to-severe atopic dermatitis, following encouraging preclinical data presented at the 2025 EAACI Congress.\nThe internally discovered ZL-1503, designed to suppress both inflammatory and itch-related pathways with an extended half-life, could meaningfully broaden Zai Lab’s immunology...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-may-respond-to-zai-lab-zlab-advancing-zl-1503","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-may-respond-to-zai-lab-zlab-advancing-zl-1503","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4548","BK4588","BK4211","BK4139","LU2488822045.USD","BK4585","ISBC","BK4531","ZLAB","BK4526"],"gpt_icon":0},{"id":"2590632500","title":"Asian Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Ends Week Flat","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632500?lang=en_us&edition=fundamental","pubTime":"2025-12-12 23:44","pubTimestamp":1765554244,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking lower Friday morning, declining 0.23% to 2,710.84 on the S&P Asia 50 ADR Index, which was little changed for the week.From","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU0390134368.USD","BK4170","LU2265009873.SGD","LX","INFY","BK4588","BK4510","LU0797268264.HKD","HDB","TLK","LU0791591158.USD","RDY.AU","IE00BYTNYM70.SGD","LU0348744763.USD","ZLAB","LU1048596156.SGD","LU1508157978.USD","PHI","LU1791710400.SGD","BK4595","RDY","LU0708995666.HKD","LU0072462343.USD","LU0261950470.USD","IE0001KFT4U8.USD","TC","BK4164","AFG","BK4548","DXF","LU0307460401.USD","BK4007","LU1481012133.USD","BK4166","BK4531","WIT","IE00B0JY6M65.USD","LU0431992006.USD","SIFY","BK4600","LU0831103253.SGD","YQ","LU1868837722.USD","IBN","DOYU","BQ","LU0181495838.USD","CAN.AU"],"gpt_icon":1},{"id":"2590247833","title":"How Investors Are Reacting To Zai Lab (ZLAB) Advancing ZL-1503 And Securing Key NRDL Renewals","url":"https://stock-news.laohu8.com/highlight/detail?id=2590247833","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590247833?lang=en_us&edition=fundamental","pubTime":"2025-12-10 01:28","pubTimestamp":1765301293,"startTime":"0","endTime":"0","summary":"Zai Lab Limited recently dosed the first participant in a global Phase 1/1b trial of ZL-1503, its internally discovered IL-13/IL-31R bispecific antibody for moderate-to-severe atopic dermatitis, and secured 2025 National Reimbursement Drug List renewal in China for VYVGART, NUZYRA, and ZEJULA.\nTogether, these developments highlight Zai Lab’s efforts to build proprietary immunology assets while preserving broad reimbursement for key in-licensed therapies in China’s healthcare system.\nWe’ll...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-are-reacting-to-zai-lab-zlab-advancing-zl-1503","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-are-reacting-to-zai-lab-zlab-advancing-zl-1503","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4139","BK4531","BK4588","ISBC","BK4548","BK4585","LU2488822045.USD","BK4211","ZLAB"],"gpt_icon":0},{"id":"2589735648","title":"Zai Lab Begins Phase 1/1b Study of Atopic Dermatitis Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735648","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735648?lang=en_us&edition=fundamental","pubTime":"2025-12-08 22:06","pubTimestamp":1765202790,"startTime":"0","endTime":"0","summary":"Zai Lab  said Monday it has dosed the first participant in a phase 1/1b trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of its experimental therapy, ZL-1503, for atopic dermatitis.The company said preclinical data showed ZL-1503 can simultaneously suppress inflammatory and itch-related pathways involved in the disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK4588","ZLAB","LU2488822045.USD","BK4585","BK4139","BK4526","BK4531"],"gpt_icon":0},{"id":"2589588543","title":"Zai Lab Says China Renews 3 Medicines in 2025 National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589588543","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589588543?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:33","pubTimestamp":1765197202,"startTime":"0","endTime":"0","summary":"Zai Lab  said Sunday that China's National Healthcare Security Administration renewed Vyvgart, Nuzyra and Zejula in its 2025 National Reimbursement Drug List.The company said Vyvgart was renewed for the treatment of certain adult patients with generalized myasthenia gravis, while Nuzyra was renewed for its oral formulation for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.Zejula was renewed for the maintenance treatment of platinum-sensitive, first-line and recurrent ovarian cancer adult patients.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4526","BK4139","BK4531","BK4548","NHLD","ZLAB","MDCO","BK4588","BK4585","LU2488822045.USD"],"gpt_icon":0},{"id":"1198560830","title":"Zai Lab (09688) Grants Stock Options and Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1198560830","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198560830?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:40","pubTimestamp":1764762039,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) announced that on December 1, 2025 (Eastern Time), the company granted options to purchase a total of 11,800 American Depositary Shares (ADS) to three grantees under the 2024 Equity...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4526","BK4531","BK1574","BK4548","BK4585","ZLAB","BK4588","BK1588","BK4139","LU2488822045.USD","09688"],"gpt_icon":0},{"id":"2588709771","title":"A Look at Zai Lab (NasdaqGM:ZLAB) Valuation Following Q3 2025 Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709771","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588709771?lang=en_us&edition=fundamental","pubTime":"2025-12-02 04:13","pubTimestamp":1764619990,"startTime":"0","endTime":"0","summary":"Zai Lab (NasdaqGM:ZLAB) just shared its Q3 2025 results, highlighting ongoing product revenue growth driven by NUZYRA and XACDURO, as well as solid progress in its clinical development pipeline.\nSee our latest analysis for Zai Lab.\nAfter a tough year for shareholders, Zai Lab's recent commercial wins and pipeline progress have sparked some optimism, but the share price still reflects lingering caution. Despite the management’s upbeat tone and new clinical milestones, the 1-year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/a-look-at-zai-lab-nasdaqgmzlab-valuation-following-q3-2025-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/a-look-at-zai-lab-nasdaqgmzlab-valuation-following-q3-2025-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4585","BK4548","LU2065732104.USD","PRGS","ZLAB","LU2488822045.USD","BK4531","BK4588","BK4139","BK4097"],"gpt_icon":0},{"id":"2588184307","title":"What Zai Lab (ZLAB)'s Q3 Results and Reaffirmed 2025 Guidance Mean for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2588184307","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588184307?lang=en_us&edition=fundamental","pubTime":"2025-12-01 01:15","pubTimestamp":1764522954,"startTime":"0","endTime":"0","summary":"Zai Lab recently presented at the Morgan Stanley 24th Asia-Pacific Summit in Singapore and announced its Q3 2025 results, highlighting progress in multiple pipeline and commercial programs, including new trial data and ongoing adoption of key therapies in China.\nA standout insight from the update is management's reaffirmation of full-year 2025 revenue guidance of at least US$460 million, signaling continued operational discipline and confidence in advancing both commercial and late-stage...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/what-zai-lab-zlabs-q3-results-and-reaffirmed-2025-guidance-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/what-zai-lab-zlabs-q3-results-and-reaffirmed-2025-guidance-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0225283273.USD","LU0234570918.USD","IE00BKVL7J92.USD","LU0158827948.USD","LU0528227936.USD","LU2111349929.HKD","LU0158827781.USD","LU1548497426.USD","LU1074936037.SGD","LU1989772840.SGD","LU2089283258.USD","LU0882574139.USD","LU2089284900.SGD","BK4548","LU1162221912.USD","LU1791710400.SGD","BK4516","LU1720051017.SGD","LU0098860793.USD","LU0971096721.USD","LU1732799900.SGD","ZLAB","BK4526","LU2133065610.SGD","LU0267386448.USD","LU2028103732.USD","BK4127","LU0320765646.SGD","LU1732800096.USD","LU0795875169.SGD","BK4504","BK4534","LU0557290698.USD","LU1244550494.USD","BK4588","LU0314104364.USD","LU2347655156.SGD","LU1720051108.HKD","LU0106831901.USD","IE00BZ1G4Q59.USD","LU1668664300.SGD","LU0795875086.SGD","LU2023251221.USD","LU1363072403.SGD","LU0006306889.USD","LU1791710582.SGD","LU0106261372.USD","LU1244550221.USD","BK4585","BK4531"],"gpt_icon":0},{"id":"1131401209","title":"Zai Lab (09688) Issues 2 Million Shares Under Equity Incentive Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=1131401209","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131401209?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:18","pubTimestamp":1763554710,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) announced that on November 19, 2025, the company issued 2 million new shares, held by a trustee, to fulfill (1) the vesting of share awards granted under the 2017, 2022, and 2024...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","ZLAB","BK4585","LU2488822045.USD","BK4526","BK4139","BK4548","BK1574","BK1588","BK4531","09688"],"gpt_icon":0},{"id":"2582135789","title":"Zai Lab Ltd Announces Share Options and Restricted Share Units Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2582135789","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582135789?lang=en_us&edition=fundamental","pubTime":"2025-11-11 17:38","pubTimestamp":1762853899,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd ( ($HK:9688) ) just unveiled an update. Zai Lab Ltd announced the grant of share options and restricted share units under its 2024 Equi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zai-lab-ltd-announces-share-options-and-restricted-share-units-grants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zai-lab-ltd-announces-share-options-and-restricted-share-units-grants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","BK4139","BK4531","BK4548","ZLAB","BK4588","BK4585","LU2488822045.USD"],"gpt_icon":0},{"id":"1110391726","title":"Zai Lab (09688) Grants Stock Options and Restricted Share Units","url":"https://stock-news.laohu8.com/highlight/detail?id=1110391726","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110391726?lang=en_us&edition=fundamental","pubTime":"2025-11-11 17:18","pubTimestamp":1762852694,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) announced that on November 10, 2025 (Eastern Time), the company granted stock options to one grantee, allowing the subscription of a total of 500 American Depositary Shares (ADS), and...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1161","BK4531","09688","ZLAB","BK4526","BK1588","BK4585","BK4588","BK1574","BK4139","BK4548"],"gpt_icon":0},{"id":"2582382545","title":"Zai Lab Ltd (1ZLB) Gets a Buy from UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2582382545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582382545?lang=en_us&edition=fundamental","pubTime":"2025-11-11 08:35","pubTimestamp":1762821313,"startTime":"0","endTime":"0","summary":"In a report released on November 7, from UBS maintained a Buy rating on Zai Lab Ltd, with a price target of HK$33.50. The company’s shares closed l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/zai-lab-ltd-1zlb-gets-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/zai-lab-ltd-1zlb-gets-a-buy-from-ubs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UBS","BK4526","BK4139","BK4531","LU1829250122.USD","BK4588","IE0034235071.USD","BK4548","BK4585","BK4118","LU2488822045.USD","ZLAB","BK4534"],"gpt_icon":0},{"id":"1117731736","title":"Stock Track | Zai Lab Plummets 5.05% Pre-Market Amid Broader Decline in Hong Kong's Innovative Drug Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1117731736","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117731736?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:38","pubTimestamp":1762526296,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd (ZLAB) shares plummeted 5.05% in pre-market trading on Friday, reflecting a broader downturn in the Hong Kong Stock Connect innovative drug sector. The decline comes on the heels of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZLAB"],"gpt_icon":0},{"id":"1143907746","title":"Hong Kong Stock Connect Innovative Drug Sector Declines in Afternoon Session, Zai Lab Plunges 10%, 520880 Drops 2% Below 10-Day Moving Average, Intraday Premium Surges","url":"https://stock-news.laohu8.com/highlight/detail?id=1143907746","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143907746?lang=en_us&edition=fundamental","pubTime":"2025-11-07 14:50","pubTimestamp":1762498246,"startTime":"0","endTime":"0","summary":"On the afternoon of November 7, the Hong Kong Stock Connect innovative drug sector followed the broader market downward, with Zai Lab (09688) plummeting nearly 10%, 3SBio dropping close to 6%, and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB","159992","09688","BK4139","BK4548","BK4585","06978","BK4588","BK1574","BK4526","BK4531","BK1588","LU2488822045.USD","BK1161","520880"],"gpt_icon":0},{"id":"1172260711","title":"Zai Lab (09688) Reports 14% YoY Revenue Growth in Q3, Totaling $116.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1172260711","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172260711?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:20","pubTimestamp":1762438830,"startTime":"0","endTime":"0","summary":"Zai Lab (09688) announced its financial results for the third quarter of 2025, with total revenue increasing by 14% year-over-year to $116.1 million. The operating loss narrowed by 28% YoY to $48.8...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","ZLAB","BK4548","BK4588","BK1161","BK4585","09688","BK1574","BK4526","BK1588","BK4531"],"gpt_icon":0},{"id":"2581536098","title":"Zai Lab Q3 Loss Narrows, Revenue Rises; 2025 Revenue Outlook Revised","url":"https://stock-news.laohu8.com/highlight/detail?id=2581536098","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581536098?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:42","pubTimestamp":1762432965,"startTime":"0","endTime":"0","summary":"Zai Lab  reported a Q3 loss Thursday of $0.33 per American depositary share, narrower than a loss of $0.42 a year earlier.Analysts polled by FactSet expected a loss of $0.29.Total revenue for the quarter ended Sept. 30 was $116.1 million, compared with $102.3 million a year earlier.Analysts surveyed by FactSet expected $141.7 million.The company said it now expects full year 2025 total revenue of at least $460 million, compared with $560 million to $590 million guidance in August.Shares of the company were down 6.7% in recent premarket activity Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","ZLAB","LU2488822045.USD","BK4585","BK4139","BK4588","BK4531","BK4526"],"gpt_icon":0},{"id":"1131927675","title":"Stock Track | Zai Lab Plunges 6.45% in Pre-market as Q3 Earnings Miss Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=1131927675","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131927675?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:38","pubTimestamp":1762432738,"startTime":"0","endTime":"0","summary":"Shares of Zai Lab Ltd (ZLAB) tumbled 6.45% in pre-market trading on Thursday following the release of its third-quarter financial results, which fell short of analysts' expectations. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZLAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.0506},{"period":"1month","weight":-0.1127},{"period":"3month","weight":-0.4789},{"period":"6month","weight":-0.5154},{"period":"1year","weight":-0.3265},{"period":"ytd","weight":-0.3265}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.10392},{"month":2,"riseRate":0.5,"avgChangeRate":0.014818},{"month":3,"riseRate":0.25,"avgChangeRate":-0.083122},{"month":4,"riseRate":0.375,"avgChangeRate":0.008126},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"Zai Lab Ltd","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zai Lab Ltd(ZLAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zai Lab Ltd,ZLAB,Zai Lab Ltd股票,Zai Lab Ltd股票老虎,Zai Lab Ltd股票老虎国际,Zai Lab Ltd行情,Zai Lab Ltd股票行情,Zai Lab Ltd股价,Zai Lab Ltd股市,Zai Lab Ltd股票价格,Zai Lab Ltd股票交易,Zai Lab Ltd股票购买,Zai Lab Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zai Lab Ltd(ZLAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zai Lab Ltd(ZLAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction